HSBC Holdings
CPRX

HSBC Holdings’s Catalyst Pharmaceutical CPRX Stock Holding History

HSBC Holdings’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$826K Sell
33,629
-24,300
-42% -$579K ﹤0.01% 1967
2025
Q4 		$1.36M Buy
57,929
+27,739
+92% +$618K ﹤0.01% 1762
2025
Q3 		$595K Sell
30,190
-21,632
-42% -$445K ﹤0.01% 2016
2025
Q2 		$1.12M Buy
51,822
+16,859
+48% +$398K ﹤0.01% 1741
2025
Q1 		$841K Sell
34,963
-1,374
-4% -$30.9K ﹤0.01% 1826
2024
Q4 		$764K Buy
36,337
+14,269
+65% +$307K ﹤0.01% 1947
2024
Q3 		$434K Sell
22,068
-10,834
-33% -$201K ﹤0.01% 2094
2024
Q2 		$504K Buy
32,902
+20,543
+166% +$320K ﹤0.01% 1958
2024
Q1 		$197K Buy
+12,359
New +$186K ﹤0.01% 2689
2023
Q1 		– Sell
-20,969
Closed -$385K – 2742
2022
Q4 		$385K Buy
20,969
+3,013
+17% +$46.4K ﹤0.01% 2404
2022
Q3 		$232K Buy
+17,956
New +$213K ﹤0.01% 2554

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HSBC Holdings's CPRX Position: Q1 2026 in Review

HSBC Holdings reduced its Catalyst Pharmaceutical (CPRX) stake by 42% in Q1 2026, selling an estimated $579K and leaving 33,629 shares worth $826K. The position accounts for ﹤0.01% of the portfolio, ranked #1967.

HSBC Holdings first reported a position in CPRX in Q3 2022 and has held it in 11 quarters since. The position peaked at $1.36M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • HSBC Holdings held 33,629 shares of Catalyst Pharmaceutical worth $826K as of Q1 2026.
  • HSBC Holdings sold 24,300 Catalyst Pharmaceutical shares in Q1 2026, an estimated $579K.
  • Catalyst Pharmaceutical made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1967 holding.
  • HSBC Holdings first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 11 quarters since.
  • HSBC Holdings's Catalyst Pharmaceutical position peaked at $1.36M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.